Clinical trial NCT06916065: A Study of Eloralintide (LY3841136) and Eloralintide With Tirzepatide in Participants With Overweight or Obesity
Official title: A Phase 1, Open-Label, Single and Multiple Dose Study to Investigate the Safety, Tolerability, and Relative Bioavailability of Single and Multiple Weekly Subcutaneous Doses of Eloralintide, and Single and Multiple Weekly Subcutaneous Doses of Eloralintide With Tirzepatide in Participants With Overweight or Obesity
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: PHASE1
Conditions: Overweight
Obesity
Lead sponsor: Eli Lilly and Company
Sponsor class: INDUSTRY
First posted: 2025-04-08
Enrollment: 188
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: BASIC_SCIENCE

Brief summary: The purpose of this study is to evaluate how well eloralintide and eloralintide with tirzepatide is tolerated and what side effects may occur in participants with overweight or obesity. The study drug will be administered subcutaneously (SC) (under the skin). Blood tests will be performed to check how much eloralintide and eloralintide with tirzepatide get into the bloodstream and how long it takes the body to eliminate it.

There will be 6 cohorts. The study will last up to approximately 26 weeks, excluding screening for Cohorts A and B, 11 weeks for Cohorts C and D, and 12 weeks for Cohorts E and F.


Eligibility criteria: Inclusion Criteria:

* Have safety laboratory test results within normal reference range for the population or investigative site, or results with acceptable deviations that are judged to be not clinically significant by the investigator. Participants with a history of thyroid disease or on thyroid medication will need to be biochemically euthyroid as assessed by measuring thyroid stimulating hormone at screening
* Have a body mass index (BMI) within the range of 27.0 to 40.0 kilogram per square meter (kg/m²), inclusive
* Have had a stable weight for the 3 months prior to screening and enrollment, that is, less than 5% body weight change

Exclusion Criteria:

* Have known allergies to related compounds of eloralintide or tirzepatide, or any of the components of the formulations
* Have significant previous or current history of comorbidities capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the investigational product; or of interfering with the interpretation of data
* Have been diagnosed with Type 1 or Type 2 diabetes mellitus, or have glycated hemoglobin greater than or equal to 6.5% or 48 millimole per mole (mmol/mol)
* Have a history of any malignancy within the past 5 years except for basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of metastatic disease for 3 years
* Have a history or presence of a gastrointestinal (GI) disorder or previous surgery that impacts gastric emptying for example, gastric bypass surgery or pyloric stenosis
* Have obesity induced by other endocrinologic disorders for example, Cushing syndrome, or diagnosed monogenetic or syndromic forms of obesity for example, Melanocortin 4 Receptor deficiency or Prader Willi syndrome
* Have a history of hypocalcemia or hypercalcemia, or abnormal laboratory values for calcium or serum phosphorus
* Have a medical history or current evidence of clinically significant cardiac condition, as per the investigator, including:

  * second or third degree heart block
  * sick sinus syndrome
  * peripheral arterial circulatory disorders
  * valvular disease
  * cardiomyopathy, or
  * other clinically significant cardiac condition
* Have taken approved or investigational medication for weight loss, including GLP-1 RAs, within the previous 3 months of study screening
* Intend to use any weight loss medications during study participation

Primary outcomes:
measure: Cohorts A and B: Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve (AUC) of Eloralintide and Tirzepatide
timeFrame: Day 106 Predose to Approximately Week 26
measure: Cohorts A and B: PK: Maximum Concentration (Cmax) of Eloralintide and Tirzepatide
timeFrame: Day 106 Predose to Approximately Week 26
measure: Cohorts C and D: PK: AUC of Eloralintide and Tirzepatide
timeFrame: Baseline Up to Approximately Week 11
measure: Cohorts C and D: PK: Cmax of Eloralintide and Tirzepatide
timeFrame: Baseline Up to Approximately Week 11
measure: Cohorts E and F: PK: AUC of Eloralintide
timeFrame: Day 8 Predose Up to Approximately Week 12
measure: Cohorts E and F: PK: Cmax of Eloralintide
timeFrame: Day 8 Predose Up to Approximately Week 12
measure: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
timeFrame: Baseline Up to Approximately Week 26
Secondary outcomes:
Other outcomes:
Locations:
city: Anaheim
country: United States
facility: Anaheim Clinical Trials, LLC
state: California
city: Daytona Beach
country: United States
facility: Fortrea Clinical Research Unit
state: Florida
city: Dallas
country: United States
facility: Fortrea Clinical Research Unit
state: Texas
Study officials:
affiliation: Eli Lilly and Company
name: Contact Lilly at 1-800-LillyRx (1-800-545-5979)
role: STUDY_DIRECTOR
References: